Physician profile
Richard Rivers
NPI 1609965136
$2,176.88
in general payments reported to CMS, 2019-2025
27 companies · $68.42 in 2025
The $68.42 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $339 · 2020: $537 · 2021: $319 · 2022: $442 · 2023: $290 · 2024: $182 · 2025: $68.42.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $540.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $540.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $288.50 | 2020-2024 | Breztri |
| Pfizer INC. | $285.45 | 2019-2024 | |
| Novo Nordisk INC | $226.63 | 2019-2024 | Ozempic, Rybelsus |
| Abbvie INC. | $224.30 | 2020-2024 | Vraylar |
| Glaxosmithkline, LLC. | $145.73 | 2019-2022 | |
| Amgen INC. | $144.15 | 2019-2024 | Prolia, Evenity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $122.46 | 2020-2023 | |
| Merck Sharp & Dohme LLC | $122.43 | 2019-2025 | Gardasil 9, M-M-R II, Rotateq |
| Lilly USA, LLC | $72.22 | 2020-2025 | Zepbound, Mounjaro |
| Amarin Pharma, INC. | $60.47 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $56.32 | 2021-2023 | |
| Abbott Laboratories | $54.63 | 2019-2023 | Freestyle Libre 3 |
| Eisai INC. | $47.25 | 2020-2021 | |
| Dexcom, INC. | $37.85 | 2023 | Dexcom G6 Transmitter |
| Exact Sciences Corporation | $37.13 | 2025 | The Cologuard Plus Collection Kit |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $30.34 | 2019 | |
| Allergan, INC. | $27.54 | 2020 | |
| Nestle Healthcare Nutrition INC. | $25.63 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $23.90 | 2022 | |
| Melinta Therapeutics, LLC | $22.46 | 2019 | |
| Xeris Pharmaceuticals, INC. | $21.92 | 2023 | Gvoke Hypopen |
| Boston Scientific Corporation | $19.36 | 2020 | |
| Optinose US, INC. | $19.01 | 2024 | |
| Sanofi-Aventis U.S. LLC | $18.59 | 2020 | |
| Biohaven Pharmaceuticals, INC. | $17.79 | 2021 | |
| Astellas Pharma US INC | $13.12 | 2023 | Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $11.70 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Rivers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.